Drugs & Therapy Perspectives

, Volume 27, Issue 4, pp 1–4 | Cite as

Aztreonam lysine for inhalation solution: a guide to its use in cystic fibrosis

Drug and Profile Reports

Aztreonam lysine for inhalation solution (AZLI) is a new option for the treatment of Pseudomonas aeruginosa lung infection in patients with cystic fibrosis. When compared with placebo in clinical trials, AZLI improved respiratory symptoms, pulmonary function and sputum P. aeruginosa density, delayed the time to need for inhaled or intravenous antipseudomonal antibacterials when used after a course of tobramycin inhalation solution, and was generally well tolerated.

What is the rationale for developing the drug?

Cystic fibrosis is a chronic genetic disease that affects the lungs, pancreas and other organs, ultimately leading to premature death.[1] A mutation in both copies of a gene results in dehydrated, thickened mucous secretions that leads to progressive obstructive airways disease and life-threatening lung infections, as well as other effects such as interference of normal pancreatic enzyme function.

Chronic infection with Pseudomonas aeruginosaand/or other pathogens is...


  1. 1.
    Plosker GL. Aztreonam lysine for inhalation solution in cystic fibrosis. Drugs 2010; 70(14): 1843–55PubMedCrossRefGoogle Scholar
  2. 2.
    Cayston powder and solvent for nebuliser solution: summary of product characteristics. London: European Medicines Agency, 2010 SepGoogle Scholar
  3. 3.
    Cayston® (aztreonam for inhalation solution): US prescribing information. Foster City (CA): Gilead Sciences, Inc., 2010 FebGoogle Scholar
  4. 4.
    McCoy K, Retsch-Bogart G, Gibson RL, et al. Microbiologic resistance and clinical efficacy of aztreonam lysine for inhalation (AZLI) in cystic fibrosis (CF) [poster no. 142]. 31st European Cystic Fibrosis Conference; 2008 Jun 11–14; PragueGoogle Scholar
  5. 5.
    McCoy K, Retsch-Bogart G, Gibson RL, et al. Relevance of established susceptibility breakpoints to clinical efficacy of inhaled antibiotic therapies in cystic fibrosis [poster no. 418]. 22nd Annual North American Cystic Fibrosis Conference; 2008 Oct 23–25; Orlando (FL)Google Scholar
  6. 6.
    Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010 Nov; 45(11): 1121–34PubMedCrossRefGoogle Scholar
  7. 7.
    Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009; 135(5): 1223–32PubMedCrossRefGoogle Scholar
  8. 8.
    McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178(9): 921–8PubMedCrossRefGoogle Scholar
  9. 9.
    Wainwright C, Nakamura C, Geller DE, et al. A double-blind, multinational, randomized, placebo-controlled trial evaluating aztreonam for inhalation (AZLI) in patients with cystic fibrosis (CF), mild lung disease and P. aeruginosa (PA) [abstract no. 81]. 33rd European Cystic Fibrosis Society Conference; 2010 Jun 16–19; ValenciaGoogle Scholar
  10. 10.
    Assael BM, La Rosa M, Knoop C, et al. Aztreonam for inhalation solution (AZLI) head to head trial, a comparative trial vs. tobramycin nebuliser solution (TNS) in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (PA): results of first treatment cycle [abstract]. 33rd European Cystic Fibrosis Society Conference; 2010 Jun 16–19; ValenciaGoogle Scholar
  11. 11.
    Quittner AL, Modi AC, Wainwright C, et al. Determination of the minimal clinically important difference scores for the cystic fibrosis questionnarie-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009; 135(6): 1610–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Personalised recommendations